Fosun Pharma: Holding Subsidiary's Sodium Thiosulfate Injection Receives Registration Approval

People’s Financial News, March 20 — Fosun Pharma (600196) announced on March 20 that its subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the drug registration application of sodium thiosulfate injection. The approved indication is for cyanide poisoning, and it can also be used for poisoning by arsenic, mercury, lead, bismuth, iodine, and other substances. The holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its subsidiaries received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of various solid tumors.

Ver originales
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
  • Recompensa
  • Comentar
  • Republicar
  • Compartir
Comentar
Añadir un comentario
Añadir un comentario
Sin comentarios
  • Anclado